Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Inclusion Criteria: * Male and female patients 18 to 80 years (inclusive) of age. * Patients are not treated for dyslipidemia with medications other than HMG-CoA reductase inhibitors (statins) for at least 4 weeks prior to Day 1. Patients should be on stable doses of current medications, if any, for at least 3 months to be eligible. * Patients must weigh at least 50 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 40 kg/m2. Exclusion Criteria: * Use of other investigational drugs at the time of enrollment * History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes * Use of lipid modifying agents (e.g. fenofibrate, niacin, omega-3 fatty acids, etc.) other than statins will exclude subjects. * Pregnant or nursing (lactating) women * Diabetic patients whose plasma glucose is not well controlled by stable diabetic treatment for at least 3 months * Heavy smokers (smoke more than 10 cigarettes a day routinely and who cannot refrain from smoking during the study). * Women of child-bearing potential (WOCBP) can be included but must use highly effective contraception * Significant illness within two (2) weeks prior to initial dosing * History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result. * A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.